Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological Response

Gastroenterology

Volumn 135, Issue 2, 2008, Pages 451-458

  Ferenci, Peter ^a   Laferl, Hermann ^b   Scherzer, Thomas Matthias ^a   Gschwantler, Michael ^c   Maieron, Andreas ^d   Brunner, Harald ^a   Stauber, Rudolf ^e   Bischof, Martin ^a   Bauer, Bernhard ^f   Datz, Christian ^g   Löschenberger, Karin ^h   Formann, Elisabeth ^c   Staufer, Katharina ^a   Steindl Munda, Petra ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c WILHELMINEN HOSPITAL   (Austria)

^d ELISABETHINEN HOSPITAL   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f LKH Hörgas Enzenbach   (Austria)

^g Krankenhaus   (Austria)

^h Roche Austria   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ERYTHROPOIETIN; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; GENOTYPE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; INFLUENZA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RECURRENT FEVER; SIDE EFFECT; UPPER ABDOMINAL PAIN; VIROLOGY; VOMITING;

EID: 48749099989     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.04.015     Document Type: Article

References (19)

1. Dienstag J.L., and McHutchison J.G. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 130 (2006) 225-230
2. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
3. Hadziyannis S.J., Sette Jr. H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
4. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
5. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
6. Jacobson I.M., Brown Jr. R.S., Freilich B., et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46 (2007) 971-981
7. Jensen D.M., Morgan T.R., Marcellin P., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43 (2006) 954-960
8. Kamal S.M., El Kamary S.S., Shardell M.D., et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 46 (2007) 1732-1740
9. Ferenci P., Fried M.W., Shiffman M.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43 (2005) 425-433
10. Berg T., von W.M., Nasser S., Sarrazin C., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 (2006) 1086-1097
11. Sanchez-Tapias J.M., Diago M., Escartin P., et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131 (2006) 451-460
12. Zeuzem S., Buti M., Ferenci P., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44 (2006) 97-103
13. Poordad F., Reddy K.R., and Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 46 (2008) 78-84
14. Dalgard O., Bjoro K., Hellum K.B., et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40 (2004) 1260-1265
15. Mangia A., Santoro R., Minerva N., et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352 (2005) 2609-2617
16. von Wagner M., Huber M., Berg T., et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129 (2005) 522-527
17. Shiffman M.L., Suter F., Bacon B.R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357 (2007) 124-134
18. Dalgard O., Bjoro K., Ring-Larsen H., et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 47 (2008) 35-42
19. Kamal S.M., El Tawil A.A., Nakano T., et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 54 (2005) 858-866